351 related articles for article (PubMed ID: 37174744)
21. Binding of FoxM1 to G2/M gene promoters is dependent upon B-Myb.
Down CF; Millour J; Lam EW; Watson RJ
Biochim Biophys Acta; 2012 Aug; 1819(8):855-62. PubMed ID: 22513242
[TBL] [Abstract][Full Text] [Related]
22. Insulin Signaling Regulates the FoxM1/PLK1/CENP-A Pathway to Promote Adaptive Pancreatic β Cell Proliferation.
Shirakawa J; Fernandez M; Takatani T; El Ouaamari A; Jungtrakoon P; Okawa ER; Zhang W; Yi P; Doria A; Kulkarni RN
Cell Metab; 2017 Apr; 25(4):868-882.e5. PubMed ID: 28286049
[TBL] [Abstract][Full Text] [Related]
23. PLK1 targets NOTCH1 during DNA damage and mitotic progression.
De Blasio C; Zonfrilli A; Franchitto M; Mariano G; Cialfi S; Verma N; Checquolo S; Bellavia D; Palermo R; Benelli D; Screpanti I; Talora C
J Biol Chem; 2019 Nov; 294(47):17941-17950. PubMed ID: 31597699
[TBL] [Abstract][Full Text] [Related]
24. The expression of Nek7, FoxM1, and Plk1 in gallbladder cancer and their relationships to clinicopathologic features and survival.
Wang R; Song Y; Xu X; Wu Q; Liu C
Clin Transl Oncol; 2013 Aug; 15(8):626-32. PubMed ID: 23359173
[TBL] [Abstract][Full Text] [Related]
25. The Mitotic Cancer Target Polo-Like Kinase 1: Oncogene or Tumor Suppressor?
de Cárcer G
Genes (Basel); 2019 Mar; 10(3):. PubMed ID: 30862113
[TBL] [Abstract][Full Text] [Related]
26. Molecular interactions of polo-like kinase 1 in human cancers.
Weng Ng WT; Shin JS; Roberts TL; Wang B; Lee CS
J Clin Pathol; 2016 Jul; 69(7):557-62. PubMed ID: 26941182
[TBL] [Abstract][Full Text] [Related]
27. Targeting polo-like kinase 1 for cancer therapy.
Strebhardt K; Ullrich A
Nat Rev Cancer; 2006 Apr; 6(4):321-30. PubMed ID: 16557283
[TBL] [Abstract][Full Text] [Related]
28. Non-mitotic functions of polo-like kinases in cancer cells.
Raab CA; Raab M; Becker S; Strebhardt K
Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188467. PubMed ID: 33171265
[TBL] [Abstract][Full Text] [Related]
29. Polo-like kinase 1, a new therapeutic target in hepatocellular carcinoma.
Mok WC; Wasser S; Tan T; Lim SG
World J Gastroenterol; 2012 Jul; 18(27):3527-36. PubMed ID: 22826617
[TBL] [Abstract][Full Text] [Related]
30. Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery.
Macůrek L; Lindqvist A; Lim D; Lampson MA; Klompmaker R; Freire R; Clouin C; Taylor SS; Yaffe MB; Medema RH
Nature; 2008 Sep; 455(7209):119-23. PubMed ID: 18615013
[TBL] [Abstract][Full Text] [Related]
31. The Functional Significance of Posttranslational Modifications on Polo-Like Kinase 1 Revealed by Chemical Genetic Complementation.
Lasek AL; McPherson BM; Trueman NG; Burkard ME
PLoS One; 2016; 11(2):e0150225. PubMed ID: 26919439
[TBL] [Abstract][Full Text] [Related]
32. Polo-like kinase-1 in DNA damage response.
Hyun SY; Hwang HI; Jang YJ
BMB Rep; 2014 May; 47(5):249-55. PubMed ID: 24667170
[TBL] [Abstract][Full Text] [Related]
33. Polo-like kinase 1 regulates cell proliferation and is targeted by miR-593* in esophageal cancer.
Ito T; Sato F; Kan T; Cheng Y; David S; Agarwal R; Paun BC; Jin Z; Olaru AV; Hamilton JP; Selaru FM; Yang J; Matsumura N; Shimizu K; Abraham JM; Shimada Y; Mori Y; Meltzer SJ
Int J Cancer; 2011 Nov; 129(9):2134-46. PubMed ID: 21170987
[TBL] [Abstract][Full Text] [Related]
34. Selective blockade of cancer cell proliferation and anchorage-independent growth by Plk1 activity-dependent suicidal inhibition of its polo-box domain.
Park JE; Kim TS; Kim BY; Lee KS
Cell Cycle; 2015; 14(22):3624-34. PubMed ID: 26513691
[TBL] [Abstract][Full Text] [Related]
35. MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells.
Joshi K; Banasavadi-Siddegowda Y; Mo X; Kim SH; Mao P; Kig C; Nardini D; Sobol RW; Chow LM; Kornblum HI; Waclaw R; Beullens M; Nakano I
Stem Cells; 2013 Jun; 31(6):1051-63. PubMed ID: 23404835
[TBL] [Abstract][Full Text] [Related]
36. Getting in and out of mitosis with Polo-like kinase-1.
van Vugt MA; Medema RH
Oncogene; 2005 Apr; 24(17):2844-59. PubMed ID: 15838519
[TBL] [Abstract][Full Text] [Related]
37. Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival.
Xiao D; Yue M; Su H; Ren P; Jiang J; Li F; Hu Y; Du H; Liu H; Qing G
Mol Cell; 2016 Nov; 64(3):493-506. PubMed ID: 27773673
[TBL] [Abstract][Full Text] [Related]
38. Polo-like kinase 1: target and regulator of transcriptional control.
Martin BT; Strebhardt K
Cell Cycle; 2006 Dec; 5(24):2881-5. PubMed ID: 17172872
[TBL] [Abstract][Full Text] [Related]
39. [Mining Polo-Box domain of Polo-like kinase 1 as a new therapeutic target for cancer].
Fu Z; Su M; Liu X; Chen Y
Sheng Wu Gong Cheng Xue Bao; 2020 Nov; 36(11):2298-2312. PubMed ID: 33244925
[TBL] [Abstract][Full Text] [Related]
40. Functional independency between catalytic activity and subcellular targeting of polo-like kinase-1: phenotypes of ectopic overexpression of various mutants.
Ji JH; Jang YJ
Cell Cycle; 2008 Jun; 7(11):1597-603. PubMed ID: 18560274
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
